OLIVE ECKSTEIN to Histiocytosis, Langerhans-Cell
This is a "connection" page, showing publications OLIVE ECKSTEIN has written about Histiocytosis, Langerhans-Cell.
Connection Strength
3.266
-
Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. Pediatr Hematol Oncol. 2023; 40(5):497-505.
Score: 0.706
-
Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
Score: 0.693
-
Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
Score: 0.538
-
Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
Score: 0.534
-
Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood. 2021 04 01; 137(13):1777-1791.
Score: 0.156
-
Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. Blood Adv. 2020 01 14; 4(1):87-99.
Score: 0.143
-
Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
Score: 0.133
-
CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
Score: 0.127
-
A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. Blood. 2017 11 16; 130(20):2229-2232.
Score: 0.122
-
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
Score: 0.114